[1] SENGOKU R. Aging and Alzheimer′s disease pathology. Neuropathology, 2020, 40(1):22-29.
[2] LIU H, ZHANG Z H, BAO X Q, et al. Molecular mechanisms of mitochondrial dynamics and mitophagy and their roles in neurodegenerative diseases. Chin Pharm J(中国药学杂志), 2020, 55(5):337-341.
[3] WANG R, FANG F. Research progress of the role of autophagy in Alzheimer′s disease and drug intervention. Chin Pharm J(中国药学杂志), 2015, 50(5):381-385.
[4] ZHANG W, XIONG B R, ZHANG L Q, et al. The role of the GABAergic system in diseases of the central nervous system. Neuroscience, 2021, 470:88-99. Doi: 10.1016/j.neuroscience.2021.06.037.
[5] LU M H, ZHAO X Y, XU D E, et al. Transplantation of GABAergic interneuron progenitor attenuates cognitive deficits of Alzheimer′s disease model mice. J Alzheimers Dis, 2020, 75(1):245-260.
[6] FU Y, LI L, WANG Y, et al. Role of GABAA receptors in EEG activity and spatial recognition memory in aged APP and PS1 double transgenic mice. Neurochem Int, 2019, 131:104542. Doi: 10.1016/j.neuint.2019.104542.
[7] TANG Y, HAN Y, YU H, et al. Increased GABAergic development in iPSC-derived neurons from patients with sporadic Alzheimer′s disease. Neurosci Lett, 2020, 735:135208. Doi: 10.1016/j.neulet.2020.135208.
[8] MAESTU F, DE HAAN W, BUSCHE M A, et al. Neuronal excitation/inhibition imbalance: core element of a translational perspective on Alzheimer pathophysiology. Ageing Res Rev, 2021, 69:101372. Doi: 10.1016/j.arr.2021.101372.
[9] ASINOF S K, PAINE T A. Inhibition of GABA synthesis in the prefrontal cortex increases locomotor activity but does not affect attention in the 5-choice serial reaction time task. Neuropharmacology, 2013, 65:39-47. Doi: 10.1016/j.neuropharm. 2012. 09. 009.
[10] MASSONE S, VASSALLO I, FIORINO G, et al. 17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease. Neurobiol Dis, 2011, 41(2):308-317.
[11] AMBRAD GIOVANNETTI E, FUHRMANN M. Unsupervised excitation: GABAergic dysfunctions in Alzheimer′s disease. Brain Res, 2019, 1707:216-226. Doi: 10.1016/j.brainres.2018.11.042.
[12] BI D, WEN L, WU Z, et al. GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer′s disease. Alzheimers Dement, 2020, 16(9):1312-1329.
[13] HEANEY C F, KINNEY J W. Role of GABA(B) receptors in learning and memory and neurological disorders. Neurosci Biobehav Rev, 2016, 63:1-28. Doi: 10.1016/j.neubiorev.2016.01.007.
[14] CHEN Z, LIU R, YANG S H, et al. Methylene blue inhibits GABAA receptors by interaction with GABA binding site. Neuropharmacology, 2017, 119:100-110. Doi: 10.1016/j.neuropharm.2017.04.002.
[15] GOVINDPANI K, CALVO-FLORES GUZMAN B, VINNAKOTA C, et al. Towards a better understanding of GABAergic remodeling in Alzheimer′s disease. Int J Mol Sci, 2017, 18(8):1813. Doi: 10.3390/ijms18081813.
[16] BELELLI D, HALES T G, LAMBERT J J, et al. GABAA receptors in GtoPdb v.2021.3. Iuphar Bps Guide Pharmacol Cite, 2021, 2021(3). Doi: 10.2218/gtopdb/F72/2021.3.
[17] GEORGE K, SADIQ N M. GABA Inhibitors . Florida: StatPearls. Treasure Island (FL), 2022.
[18] JANKOVIC S M, DJESEVIC M, JANKOVIC S V. Experimental GABA A receptor agonists and allosteric modulators for the treatment of focal epilepsy. J Exp Pharmacol, 2021, 13:235-244.
[19] BHAGAT K, SINGH J V, PAGARE P P, et al. Rational approaches for the design of various GABA modulators and their clinical progression. Mol Divers, 2021, 25(1):551-601.
[20] SHARMA K, PRADHAN S, DUFFY L K, et al. Role of receptors in relation to plaques and tangles in Alzheimer′s disease pathology. Int J Mol Sci, 2021, 22(23). Doi: 10.3390/ijms222312987.
[21] KWAKOWSKY A, WALDVOGEL H J, FAULL R L M. Therapeutic potential of alpha 5 subunit containing GABAA receptors in Alzheimer′s disease. Neural Regen Res, 2021, 16(8):1550-1551.
[22] NAVA-MESA M O, JIMENEZ-DIAZ L, YAJEYA J, et al. GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer′s disease. Front Cell Neurosci, 2014, 8:167. Doi: 10.3389/fncel.2014.00167.
[23] YOSHIIKE Y, KIMURA T, YAMASHITA S,et al. GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One, 2008, 3(8):e3029. Doi: 10.1371/journal.pone.0003029.
[24] AVOLIO E, MAHATA S K, MANTUANO E, et al. Antihypertensive and neuroprotective effects of catestatin in spontaneously hypertensive rats: interaction with GABAergic transmission in amygdala and brainstem. Neuroscience, 2014, 270:48-57.
[25] HU B, GENG C, GUO F, et al. GABAA receptor agonist muscimol rescues inhibitory microcircuit defects in the olfactory bulb and improves olfactory function in APP/PS1 transgenic mice. Neurobiol Aging, 2021, 108:47-57. Doi: 10.1016/j.neurobiolaging.2021.08.003.
[26] CASTELLANO C, MCGAUGH J L. Effects of post-training bicuculline and muscimol on retention: lack of state dependency. Behav Neural Biol, 1990, 54(2):156-164.
[27] PILIPENKO V, NARBUTE K, BEITNERE U, et al. Very low doses of muscimol and baclofen ameliorate cognitive deficits and regulate protein expression in the brain of a rat model of streptozocin-induced Alzheimer′s disease. Eur J Pharmacol, 2018, 818:381-399.
[28] PILIPENKO V, NARBUTE K, PUPURE J, et al. Neuroprotective action of diazepam at very low and moderate doses in Alzheimer′s disease model rats. Neuropharmacology, 2019, 144:319-326.
[29] PETRACHE A L, RAJULAWALLA A, SHI A, et al. Aberrant excitatory-inhibitory synaptic mechanisms in entorhinal cortex microcircuits during the pathogenesis of Alzheimer′s disease. Cereb Cortex, 2019, 29(4):1834-1850.
[30] SHAO H, ZHANG Y, DONG Y, et al. Chronic treatment with anesthetic propofol improves cognitive function and attenuates caspase activation in both aged and Alzheimer′s disease transgenic mice. J Alzheimers Dis, 2014, 41(2):499-513.
[31] MOHR E, BRUNO G, FOSTER N, et al. GABA-agonist therapy for Alzheimer′s disease. Clin Neuropharmacol, 1986, 9(3):257-263.
[32] CHEN C Y, DI LUCENTE J, LIN Y C, et al. Defective GABAergic neurotransmission in the nucleus tractus solitarius in Mecp2-null mice, a model of Rett syndrome. Neurobiol Dis, 2018, 109(Pt A):25-32.
[33] LIND B L, JESSEN S B, LONSTRUP M, et al. Fast Ca(2+) responses in astrocyte end-feet and neurovascular coupling in mice. Glia, 2018, 66(2):348-358.
[34] LI Y, ZHU K, LI N, et al. Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model. Alzheimers Res Ther, 2021, 13(1):114.
[35] JOHNSTON G A. Advantages of an antagonist: bicuculline and other GABA antagonists. Br J Pharmacol, 2013, 169(2):328-336.
[36] YANOVSKY Y, SCHUBRING S R, YAO Q, et al. Waking action of ursodeoxycholic acid (UDCA) involves histamine and GABAA receptor block. PLoS One, 2012, 7(8):e42512. Doi: 10.1371/journal.pone.0042512.
[37] MATSUYAMA S, TANIGUCHI T, KADOYAMA K, et al. Long-term potentiation-like facilitation through GABAA receptor blockade in the mouse dentate gyrus in vivo. Neuroreport, 2008, 19(18):1809-1813.
[38] DE WILDE M C, OVERK C R, SIJBEN J W, et al. Meta-analysis of synaptic pathology in Alzheimer′s disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement, 2016, 12(6):633-644.
[39] KADOYAMA K, MATSUURA K, TAKANO M, et al. Proteomic analysis involved with synaptic plasticity improvement by GABAA receptor blockade in hippocampus of a mouse model of Alzheimer′s disease. Neurosci Res, 2021, 165:61-68. Doi: 10.1016/j.neures.2020.04.004.
[40] KAZIM S F, CHUANG S C, ZHAO W, et al. Early-onset network hyperexcitability in presymptomatic Alzheimer′s disease transgenic mice is suppressed by passive immunization with anti-human APP/Abeta antibody and by mGluR5 blockade. Front Aging Neurosci, 2017, 9:71. Doi: 10.3389/fnagi.2017.00071.
[41] LANDFIELD P W, BASKIN R K, PITLER T A. Brain aging correlates: retardation by hormonal-pharmacological treatments. Science, 1981, 214(4520):581-584.
[42] BEZZINA C, VERRET L, HALLEY H, et al. Environmental enrichment does not influence hypersynchronous network activity in the Tg2576 mouse model of Alzheimer′s disease. Front Aging Neurosci, 2015, 7:178. Doi: 10.3389/fnagi.2015.00178.
[43] KUMAR K, KAUR H, DESHMUKH R. Neuroprotective role of GABAB receptor modulation against streptozotocin-induced behavioral and biochemical abnormalities in rats. Neuroscience, 2017, 357:67-74. Doi: 10.1016/j.neuroscience.2017.05.054.
[44] SUN Z, SUN L, TU L. GABAB receptor-mediated PI3K/Akt signaling pathway alleviates oxidative stress and neuronal cell injury in a rat model of Alzheimer′s disease. J Alzheimers Dis, 2020, 76(4):1513-1526.
[45] FU Y, CUI J, MA Y. Differential effects of aging on EEG after baclofen administration. Sci China Life Sci, 2011, 54(5):459-465.
[46] CASTELLANO C, BRIONI J D, NAGAHARA A H, et al. Post-training systemic and intra-amygdala administration of the GABA-B agonist baclofen impairs retention. Behav Neural Biol, 1989, 52(2):170-179.
[47] KREIS A, DESLOOVERE J, SUELVES N, et al. Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission. Sci Rep, 2021, 11(1):17600. Doi: 10.1038/s41598-021-97144-3.
[48] FROESTL W, GALLAGHER M, JENKINS H, et al. SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol, 2004, 68(8):1479-1487.
[49] ALMASI A, ZAREI M, RAOUFI S, et al. Influence of hippocampal GABAB receptor inhibition on memory in rats with acute beta-amyloid toxicity. Metab Brain Dis, 2018, 33(6):1859-1867.
[50] CHEN M, CHEN Y, HUO Q, et al. Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models. Mol Neurodegener, 2021, 16(1):14. Doi: 10.1186/s13024-021-00434-7.
[51] LASARGE C L, BANUELOS C, MAYSE J D, et al. Blockade of GABA(B) receptors completely reverses age-related learning impairment. Neuroscience, 2009, 164(3):941-947.
[52] JENSEN R J. Blocking GABA(C) receptors increases light responsiveness of retinal ganglion cells in a rat model of retinitis pigmentosa. Exp Eye Res, 2012, 105:21-26. Doi: 10.1016/j.exer.2012.10.005.
[53] CUNHA C, MONFILS M H, LEDOUX J E. GABA(C) Receptors in the lateral amygdala: a possible novel target for the treatment of fear and anxiety disorders?. Front Behav Neurosci, 2010, 4:6. Doi: 10.3389/neuro.08.006.2010.
[54] GIBBS M E, JOHNSTON G A. Opposing roles for GABAA and GABAC receptors in short-term memory formation in young chicks. Neuroscience, 2005, 131(3):567-576.
[55] ARNAUD C, GAUTHIER P, GOTTESMANN C. Study of a GABAC receptor antagonist on sleep-waking behavior in rats. Psychopharmacology (Berl), 2001, 154(4):415-419.
[56] SAMAKASHVILI S, IBANEZ C, SIMO C, et al. Analysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease. Electrophoresis, 2011, 32(19):2757-2764.
[57] LANCTOT K L, HERRMANN N, MAZZOTTA P, et al. GABAergic function in Alzheimer′s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry, 2004, 49(7):439-453.
[58] LIMON A, REYES-RUIZ J M, MILEDI R. Loss of functional GABA(A) receptors in the Alzheimer diseased brain. Proc Natl Acad Sci USA, 2012, 109(25):10071-10076.
[59] KAWASAKI K, EIGYO M, IKEDA M, et al. A novel benzodiazepine inverse agonist, S-8510, as a cognitive enhancer. Prog Neuropsychopharmacol Biol Psychiatry, 1996, 20(8):1413-1425.
[60] AHTIAINEN A, GENOCCHI B, TANSKANEN J M A, et al. Astrocytes exhibit a protective role in neuronal firing patterns under chemically induced seizures in neuron-astrocyte co-cultures. Int J Mol Sci, 2021, 22(23). Doi: 10.3390/ijms222312770.
[61] YOON J K, KIM J, SHAH Z, et al. Advanced human BBB-on-a-chip: a new platform for Alzheimer′s disease studies. Adv Healthc Mater, 2021, 10(15):e2002285. Doi: 10.1002/adhm.202002285.